Pharmacological Management of Osteoporosis in Postmenopausal Women
Key Points
Key Points
- Treat high risk individuals - particularly those with previous fracture.
- Consider bisphosphonates as the first line therapeutic choice for postmenopausal women at high risk of fracture.
- Reassess fracture risk after patient has been on bisphosphonates for 3-5 years.
- Following reassessment, prescribe a “bisphosphonate holiday” for women who are on bisphosphonates and are low-to-moderate risk of fracture.
- Consider anabolic therapy (teriparatide or abaloparatide) for women at very high risk of fractures, including those with multiple fractures.
- All women undergoing treatment with osteoporosis therapies other than anabolic therapy should consume calcium and vitamin D in their diet or via supplements.
- Monitor the BMD of high-risk individuals with a low BMD every 1 to 3 years.
Treatment and Management
...atment and Management...
...to Treat
1.1: Endocrine Society (ES) recommends tr...
...sphosphonates...
...1: In postmenopausal women at high risk of fractur...
...opausal women with osteoporosis who are taking...
...osumab...
...In postmenopausal women with osteop...
...menopausal women with osteoporosis who are tak...
...: In postmenopausal women with osteopo...
...eriparatide and Abalopa...
....1: In postmenopausal women with os...
...menopausal women with osteoporosis who ha...
...osozumab...
....1: In postmenopausal women with osteoporosis a...
...menopausal women with osteoporosis who have...
Selective Estrogen Receptor Modulators
...postmenopausal women with osteoporosis...
...l Hormone Therapy and Tibolone...
...In postmenopausal women at high risk of fr...
...nopausal women with osteoporosis at high...
...citonin...
7.1: In postmenopausal women at high risk of...
...cium and Vitamin...
...tmenopausal women with low BMD and at h...
....2: In postmenopausal women at high ri...
Monitoring
...tmenopausal women with a low BMD and at high...
...Algorithm for the Management of Postmenopausa...